Topical Hemostatic Agents at Time of Obstetric and Gynecologic
2020年7月13日 · Topical hemostatic agents should not be used for routine prophylaxis of postoperative bleeding because these agents may increase the risk of infection, adhesion formation, and other complications. Topical hemostatic agents have distinct mechanisms of action, different potential adverse effect profiles, and varying costs.
Screening and Management of Bleeding Disorders in Adolescents …
Perioperative hemostatic agents include desmopressin acetate and antifibrinolytic medications (eg, aminocaproic acid, tranexamic acid). Currently, no standardized protocol exists for operative placement of the LNG-IUD in the patient with a bleeding disorder.
Committee Opinion - ACOG
Topical Hemostatic Agents at Time of Obstetric and Gynecologic Surgery ...
Management of Acute Abnormal Uterine Bleeding in Nonpregnant …
Kadir RA, Lukes AS, Kouides PA, Fernandez H, Goudemand J. Management of excessive menstrual bleeding in women with hemostatic disorders. Fertil Steril 2005;84:1352–9. [ PubMed ] [Full Text]
Nonobstetric Surgery During Pregnancy - ACOG
No currently used anesthetic agents have been shown to have any teratogenic effects in humans when using standard concentrations at any gestational age. There is no evidence that in utero human exposure to anesthetic or sedative drugs has any effect on the developing fetal brain; and there are no animal data to support an effect with limited ...
Von Willebrand Disease in Women - ACOG
Nonhormonal treatment options include antifibrinolytic agents, such as tranexamic acid and ε-aminocaproic acid 27 28, and treatments that increase endogenous plasma concentration of vWF, replace vWF, or promote hemostasis without affecting vWF. Antifibrinolytics inhibit the conversion of plasminogen to plasmin, which inhibits fibrinolysis and ...
CREOG Educational Objectives - ACOG
Annotations. The CREOG Education Committee annotated the 13th edition of the CREOG Educational Objectives with educational resources listed in the first column in red, with Milestones listed in the second column in blue and with ACGME requirements listed where appropriate from the Common and OBGYN requirements in the third column in green.
Hemoglobinopathies in Pregnancy - ACOG
Neither ACOG nor its officers, directors, members, employees, or agents will be liable for any loss, damage, or claim with respect to any liabilities, including direct, special, indirect, or consequential damages, incurred in connection with this …
Postmenopausal Estrogen Therapy Route of Administration and …
Post MS, Christella M, Thomassen LG, van derMooren MJ, vanBaal WM, Rosing J, et al. Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis: a randomized, placebo-controlled study in postmenopausal women. Arterioscler Thromb Vasc Biol 2003;23:1116–21.
ACOG Clinical | ACOG
ACOG clinical content is the indispensable decision support resource for women's healthcare providers--reliable and relevant, grounded in scientific evidence, and developed through a rigorous and inclusive process.